ALK

Allergy solutions for life

Read more about ALK's growth strategy
Quality of life

Under­standing allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.

understanding_allergy

Watch the presentation

News

See all
  • Post date
    03/13/2019
    Annual General Meeting in ALK-Abelló A/S held on 13 March 2019
    Read more
  • Post date
    03/12/2019
    The pollen season kicks off with an award-winning pollen app
    Read more
  • Post date
    03/04/2019
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
    Read more
  • Post date
    02/26/2019
    New data shows ALK’s house dust mite SLIT-tablet significantly improves quality of sleep for allergic rhinitis patients
    Read more
  • Post date
    02/14/2019
    Annual General Meeting in ALK-Abelló A/S on 13 March 2019
    Read more
  • Post date
    02/07/2019
    ALK releases its annual report 2018
    Read more
  • Post date
    01/30/2019
    Release date of annual report 2018 for ALK and audio cast
    Read more
  • Post date
    01/15/2019
    Large-scale paediatric SLIT-tablet trial meets primary endpoint, confirming potential in children
    Read more
  • Post date
    01/15/2019
    ALK's Board of Directors to nominate Vincent Warnery as new member of the Board
    Read more
ALK launches growth strategy
Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.
Read more
Growth strategy: Establish and succeed in North America
North America is the world's largest allergy market, with over 50 million allergy sufferers, and it offers ALK the greatest medium-term growth potential. For example, there are around 10 million AIT-eligible allergy sufferers in the USA alone, just one-third of whom actually receive AIT today.
Read more
Growth strategy: Complete the tablet portfolio for all relevant ages
ALK is committed to offering a full portfolio of tablets for all relevant ages, covering the five most common global respiratory allergies.
Read more
Growth strategy: Patient engagement systems and adjacent business
ALK will establish a new commercial consumer care division to drive digital patient engagement with the ultimate aim of creating new value from ALK's expanded allergy presence.
Read more
Allergy solutions for life

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Read more about ALK
Global presence
ALK employs around 2,300 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
Read more about our global presence
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
Read more about our pipeline
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.
Read more about our heritage